Uitto J, Pulkkinen L
Departments of Dermatology and Cutaneous Biology, Jefferson Medical College, and Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Hum Gene Ther. 2000 Nov 1;11(16):2267-75. doi: 10.1089/104303400750035807.
Tremendous progress has been made in understanding the genetic basis of different forms of genodermatoses, a group of heritable diseases displaying a spectrum of phenotypic manifestations and clinical severity. The information about the underlying mutations in the candidate gene/protein systems has provided the basis for initial development of cutaneous gene therapy, and these heritable conditions appear to serve as appropriate candidate diseases for such efforts. Because of its accessibility and the fact that resident skin cells, such as epidermal keratinocytes and dermal fibroblasts, can be readily propagated in culture, skin serves as an appropriate target tissue for gene therapy. Various strategic considerations, including the use of in vivo or ex vivo approaches, gene replacement versus gene repair, utilization of different delivery systems, etc., require careful prioritization depending on the type of mutations and their pathogenetic consequences at the mRNA and protein levels.
在理解不同类型遗传性皮肤病的遗传基础方面已经取得了巨大进展。遗传性皮肤病是一组具有一系列表型表现和临床严重程度的遗传性疾病。关于候选基因/蛋白质系统中潜在突变的信息为皮肤基因治疗的初步发展提供了基础,而且这些遗传性疾病似乎是此类研究的合适候选疾病。由于皮肤易于接触,并且诸如表皮角质形成细胞和真皮成纤维细胞等驻留皮肤细胞能够在培养中轻松繁殖,因此皮肤是基因治疗的合适靶组织。各种战略考量,包括体内或体外方法的使用、基因替代与基因修复、不同递送系统的利用等,需要根据突变类型及其在mRNA和蛋白质水平上的致病后果仔细进行优先级排序。